Involution of infantile haemangiomas after imiquimod 5% cream

Barry, Robert; Hughes, B.R.; Cook, Leanne

doi:10.1111/j.1365-2230.2007.02676.x

Cited by 38 publications

(38 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imiquimod as 5% cream has also recently been described for the treatment of severe complicated hemangiomas. However, side effects and the small study size make further studies necessary in order to assess this therapeutic option [20].…”

Section: Discussionmentioning

confidence: 99%

Congenital Lesions of Tip of Nose: Report of Two Cases with Review

Goyal¹,

Goyal²,

Saini³

et al. 2015

OALib

View full text Add to dashboard Cite

Tip of nose is most prominent part of the face. It has an aesthetic importance as well as influence on the psyche of children. Midline congenital lesions like dermoid cyst and haemangioma confined to the tip of nose are rare. Being midline structure of body congenital condition like dermoid cyst occurs due to the sequestration of the skin along the lines of embryonic closure. Haemangioma is another common congenital lesion of face in childhood. But haemangioma confined only to tip of nose is uncommon. We present these two uncommon congenital lesions of tip of nose.

show abstract

Section: Discussionmentioning

confidence: 99%

Congenital Lesions of Tip of Nose: Report of Two Cases with Review

Goyal¹,

Goyal²,

Saini³

et al. 2015

OALib

View full text Add to dashboard Cite

show abstract

“…Early intervention may limit some sequelaes such as ulcerations and tissue necrosis during the fast proliferating phase, or residual skin changes after spontaneous involution (Welsh et al, 2004). Several American and European reports have suggested the efficacy and safety of the topical application of imiquimod in the treatment of IHs (Martinez et al, 2002;Welsh et al, 2004;Hazen et al, 2005;Ho et al, 2007;Barry et al, 2008;McCuaig et al, 2009). In this report, 25 Chinese pediatric patients with various cutaneous vascular disorders were treated with topical imiquimod and evaluated for the therapeutic response and tolerability.…”

Section: Introductionmentioning

confidence: 99%

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Mao¹,

Wang²,

Yan³

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To evaluate the clinical effect of topical imiquimod treatment on cutaneous vascular disorders in pediatric patients. Methods: A retrospective investigation was conducted in 25 pediatric patients with cutaneous vascular disorders, including 19 infantile hemangiomas (IHs) (12 superficial/7 mixed type), 5 nevus flammeus (NF), and 1 pyogenic granuloma (PG). Imiquimod 5% cream was applied every other day for 4 to 16 weeks (average 9.6 weeks). Results: Of the 19 IHs treated, an overall efficacy of 52.6% was achieved, with a clinical resolution rate of 15.8%, excellent rate of 26.3%, and moderate rate of 10.5%. The superficial type responded the best at 66.7%, while the mixed type showed only 28.6% effectiveness, which was predominantly from their superficial parts. No obvious response was noted in the 5 patients with NF. Side effects were observed in 78.9% of the patients, mostly mild to moderate local irritations and occasionally severe reactions such as thick crusting and ulceration. Systemic side events were observed in 4 IH patients including fever and digestive tract reactions. No recurrence was observed during the follow-up examination. Conclusions: Topical imiquimod could be an alternative option for the treatment of uncomplicated superficial IHs with satisfactory tolerability.

show abstract

“…The drug was applied 3 times a week for the first 4 weeks, followed by 5 times a week until achievement of desired results. This pioneering report was followed by several other case/series reports and trials (20)(21)(22)(23).…”

Section: Timolol Maleatementioning

confidence: 99%

“…imiquimod 3 times per week. In case of unsatisfactory response after 4 weeks, the frequency of application may be increased to 5-7 times a week (20)(21)(22)(23). The average duration of treatment is 16 weeks, but this period may be prolonged or shortened if necessary.…”

Section: Imiquimodmentioning

confidence: 99%

See 1 more Smart Citation

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Semkova¹,

Marina²,

Kazandjieva³

2011

Serbian Journal of Dermatology and Venerology

View full text Add to dashboard Cite

Infantile hemangiomas are the most common, benign vascular tumors of infancy. Their main feature is spontaneous involution over months to years after an initial phase of rapid proliferation. Small, superficial lesions usually resolve without sequel, but scarring and disfigurement are still possible, while the cosmetic outcome is unpredictable. Thus, inflantile hemangiomas benefit from non-aggressive topical treatment, because it is safe and with an overall outcome comparable to spontaneous involution. The available topical agents reported in the literature to satisfy these requirements are topical beta-blockers, imiquimod and topical corticosteroids. However, none of these have been assessed in randomized controlled trials, and standardized treatment recommendations about precise dosing and patient selection are not available yet.

show abstract

Involution of infantile haemangiomas after imiquimod 5% cream

Cited by 38 publications

References 11 publications

Congenital Lesions of Tip of Nose: Report of Two Cases with Review

Congenital Lesions of Tip of Nose: Report of Two Cases with Review

Topical imiquimod treatment of cutaneous vascular disorders in pediatric patients: clinical evaluation on the efficacy and safety

Topical Treatment of Infantile Hemangiomas – Where Are We Now? / Topikalni tretman infantilnih hemangioma – gde smo danas?

Contact Info

Product

Resources

About